Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchApremilastApremilast (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
  Download Image
    
Share
  
Post
Apremilast for COVID-19
2 studies from 92 scientists
594 patients in 1 country
No significant improvements are seen in meta analysis to date.
COVID-19 Apremilast studies. Nov 2024. c19early.org
0 0.5 1 1.5+ All studies -3% Mortality -3% Recovery -19% RCTs -3% RCT mortality -3% Late -3% Favorsapremilast Favorscontrol
Home   Post   Share   @CovidAnalysis   OutcomesOutcomes   Recent:
Xie. Submit updates/corrections. Summary.
ApremilastAll
Nov 8
 Xie et al., Cellular & Molecular Biology Letters, doi:10.1186/s11658-024-00659-6 The role of reactive oxygen species in severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection-induced cell death
Review of the effects of reactive oxygen species (ROS) on cell death pathways in SARS-CoV-2 infection. SARS-CoV-2 induces oxidative stress and ROS generation which can lead to several types of regulated cell death including NETosis, ferro..
Mar 3
2023
 Files et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889 Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
5% higher mortality (p=0.85) and 28% worse recovery (p=0.22). RCT severe COVID-19 patients showing no significant difference in outcomes with apremilast.
Apr 7
2022
 Amgen, NCT04590586 Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
1% higher mortality (p=1), 8% worse improvement (p=0.73), 11% lower hospital discharge (p=0.56), and 11% worse recovery (p=0.58). RCT 384 hospitalized patients showing no significant difference with apremilast treatment.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0